Unique ID issued by UMIN | UMIN000018155 |
---|---|
Receipt number | R000021028 |
Scientific Title | Clinical and Neural Changes of CBT in patients with Major Depression: a Randomized Clinical Trial with fMRI investigation |
Date of disclosure of the study information | 2015/07/01 |
Last modified on | 2021/06/09 18:35:14 |
Clinical and Neural Changes of CBT in patients with Major Depression: a Randomized Clinical Trial with fMRI investigation
IMAGING study
Clinical and Neural Changes of CBT in patients with Major Depression: a Randomized Clinical Trial with fMRI investigation
IMAGING study
Japan |
Major Depressive Disorder
Psychiatry |
Others
NO
The primary object of this study is to compare brain functional change between cognitive behavioral therapy and talking control during future thinking task in patients with major depression.
We will also evaluate clinical and neuropsychological outcomes of depression.
Others
brain activity
Exploratory
Pragmatic
Phase II
BOLD signal during future thinking task recorded by fMRI
-Depression symptoms: GRID-Hamilton Depression Rating Scale, Beck Depression Inventory, Quick Inventory of Depressive Symptomatology
-Remission: defined as HAMD-17=<7
-Response: defined as 50% reduction of baseline HAMD-17total score
-Dysfunctional attitude: Dysfunctional Attitude Scale,
-Automatic thoughts: Automatic Thoughts Questionnaire Revised,
QOL: EuroQol
-Cognitive function: Word Fluency test, Digit Symbol Substitution test
Interventional
Parallel
Randomized
Individual
Single blind -investigator(s) and assessor(s) are blinded
Active
YES
NO
Institution is not considered as adjustment factor.
YES
Central registration
2
Treatment
Behavior,custom | Other |
Cognitive Behavioral Therapy
Talking Control
20 | years-old | <= |
70 | years-old | >= |
Male and Female
1. Subjects with DSM-IV Major Depressive Disorder based on Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorder (SCID) at screening.
2. Subjects with HAMD-17 score >=16 at screening.
3. Subjects who give full consent in the participation of the study.
1. No comorbid alcohol or substance use disorder in 2 years prior to the screening.
2. No history or concurrent manic or psychotic episode.
3. No other primary DSM-IV Axis I Disorders in 6 months prior to the screening.
4. No comorbid of antisocial personality disorder.
5. No serious and imminent suicidal ideation at screening.
6. Unlikely to attend more than 8 visits during the 16-week trial phase (eg, due to relocation).
7. Have previously completed an individual CBT programme.
8. No organic brain lesions or major cognitive deficits in a year prior to the screening.
9. No severe or unstable medical illness at screening.
10. Contraindication to MRI (including cardiac pacemaker, claustrophobia)
38
1st name | |
Middle name | |
Last name | Atsuo Nakagawa, MD, PhD |
Keio University School of Medicine
Center for Clinical Research
Shinanomachi 35, Shinjuku-ku, Tokyo, Japan
03-5363-3235
anakagawa@keio.jp
1st name | |
Middle name | |
Last name | Atsuo Nakagawa, MD, PhD |
Keio University School of Medicine
Center for Clinical Research
Shinanomachi 35, Shinjuku-ku, Tokyo, Japan
03-5363-3235
anakagawa@keio.jp
Keio Imaging Study Group
Grant-in-Aid for Scientific Research
Japanese Governmental office
Japan
NO
慶應義塾大学医学部/慶應義塾大学病院(東京都)
2015 | Year | 07 | Month | 01 | Day |
Unpublished
Completed
2015 | Year | 05 | Month | 19 | Day |
2015 | Year | 06 | Month | 22 | Day |
2015 | Year | 07 | Month | 22 | Day |
2020 | Year | 06 | Month | 30 | Day |
2015 | Year | 07 | Month | 01 | Day |
2021 | Year | 06 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000021028
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |